ETFs AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 10:38:15 16/07/2024 BST 5-day change 1st Jan Change
12,045 GBX -0.49% Intraday chart for AstraZeneca PLC +1.05% +13.87%

ETFs positioned on AstraZeneca PLC

Name Weight AuM 1st Jan change Investor Rating
9.20% 11 M€ +0.83% -
5.39% 218 M€ +18.24%
5.17% 21 M€ +12.10% -
4.89% 801 M€ +12.31%
4.11% 88 M€ +10.37% -
3.47% 262 M€ +8.80%
2.74% 4 M€ -.--% -
2.57% 6 M€ -.--%
2.53% 7 M€ +8.64% -
2.53% 664 M€ +8.63%
1.54% 29 M€ +8.37% -
1.51% 2 M€ +9.19% -
1.51% 2 M€ -.--% -
1.26% 12 M€ +15.09% -
1.19% 51 M€ +7.91%
1.16% 10 M€ -3.35% -
0.97% 7 M€ +7.14% -
0.89% 35 M€ +7.66% -
0.86% 276 M€ +11.40% -
0.70% 261 M€ -.--% -
0.69% 200 M€ +15.94% -
0.69% 488 M€ +18.08%
0.57% 205 M€ -.--%
0.54% 284 M€ -.--%
0.51% 23 M€ -.--% -
0.51% 786 M€ -.--%
0.50% 206 M€ -.--%
0.48% 749 M€ +11.10%
0.43% 288 M€ +28.93%
0.38% 607 M€ +0.05% -
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
157.2 USD
Average target price
177.6 USD
Spread / Average Target
+13.00%
Consensus